Introduction
Polycyclic aromatic hydrocarbons (PAHs) are metabolized to various products by xenobiotic (drug)-metabolizing enzymes such as cytochrome P450 (P450 or CYP), epoxide hydrolase (EH), glutathione transferase (GST), UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), NAD(P)H quinone oxidoreductase 1 (NQO1), and aldo-keto reductase (AKR). [1] [2] [3] P450s play key roles in the initial step of oxidation of PAHs to phenols and oxides. The oxygenated (intermediate) products are further metabolized to more polar products by so-called phase II enzymes and the resultant metabolites are usually more soluble in water than the parent compounds and can be excreted from the body. 3) Benzo[a]pyrene (B[a]P), a prototype of carcinogenic PAHs, has been shown to be activated by xenobioticmetabolizing enzymes to highly mutagenic and carcinogenic metabolites that initiate cell transformation (Fig. 1) . 1) Historically, a K-region oxide, B[a]P-4,5-oxide, was thought to be an ultimate carcinogenic metabolite. 1, 2) However, the 4,5-oxide, an oxidation product of B[a]P by P450s, was found to be readily hydrolyzed by EH to an inactive B[a]P-4,5-diol and waŝ nally concluded not to play major roles in B[a]P carcinogenesis.
1) Subsequent examination of several B[a]P metabolites revealed that B[a]P-7,8-diol-9,10-epoxides, commonly referred to as bay region oxides, that are formed through metabolism of B[a]P by P450 and EH, are highly reactive toward DNA and, thus are identiˆed to be ultimate carcinogenic metabolites. 1, 4) Recent studies showed that human CYP1 enzymes, CYP1A1, 1A2, and 1B1, have key roles in activating B[a]P and other PAHs to their diol-epoxides (also called as bayand fjord-region epoxides). 3, 5) Although major activation pathway for PAHs is considered to be the formation of diol-epoxides, PAHs are also activated by other enzymatic activities (Fig. 1) . First, B[a]P is converted to radical cations through one-electron oxidation mechanism by peroxidase activity and the resultant products can react with DNA to form unstable depurinating adducts. 6) However, it remains unclear whether this activation step is really involved in chemical carcinogenesis by B[a]P in vivo and which enzymes participate in the formation of B[a]P radical cations. 6, 7) Second, AKR has been shown to convert B[a]P-7,8-diol to reactive B[a]P o-quinone (B[a]P-7,8-dione) via B[a]P-catechols. 8) The reactive B[a]P o-quinone is able to interact with DNA, forming stable and depurinating DNA adducts. Thus, PAHdiols can be activated by two enzymatic activities; one is to form PAH diol-epoxides by P450s and the other is PAH o-quinones by AKR. 1, 9) Finally, it is proposed that B[a]P 1,3-, 1,6-, and 3,6-quiones formed through metabolism of B[a]P by P450s are proximate carcinogenic metabolites, and these quinine derivatives are detoxiˆed by NQO1 as evidenced by the results that disruption of NQO1 in mice causes decrease in B[a]Pinduced skin carcinogenicity in vivo. 10, 11) As mentioned above, PAHs and their reactive metabolites are further converted by so-called phase II enzymes such as EH, UGT, GST, SULT, NQO1, and AKR to more polar and detoxiˆed metabolites (Fig. 1) . 3) Recent studies have established that there are large inter-individual diŠerences in levels of expression and catalytic activities of a variety of xenobiotic-metabolizing enzymes and these phenomena are thought to be key factors in understanding the basis of diŠerent susceptibilities of individuals toward xenobiotic chemicals including PAHs.
3) Factors aŠecting such variations include induction and inhibition of enzymes by diverse chemicals and genetic polymorphisms of xenobiotic-metabolizing enzymes in humans. 3, 5) In this review, we focus on our recent understandings of the roles of human CYP1 enzymes in the activation of PAHs to reactive metabolites. Induction and inhibition of these enzymes by diverse chemicals are discussed with respect to chemical carcinogenesis. Finally, relationships between genetic polymorphisms of enzymes that activate and detoxify PAHs and cancer susceptibilities in humans are brie‰y described. 4,12) Although these four diol-epoxides were highly mutagenic when assessed in Ames Salmonella tester strains and Chinese hamster V79 cells, (＋)-B[a]P-7, 8-diol-9, 10-oxide-2 was identied to be the most reactive in producing tumors in newborn mice. 4, 12) The bay and fjord region theory has also been applied to other PAHs including
-diol, and 7,12-DMBA-3,4-diol (Fig. 3) . 1, 2, 4, 5, 13) Historically, CYP1A1 had been thought to be uniquely responsible for metabolic activation of most of the carcinogenic PAHs in experimental animals. 1, 2, 14) In 1990, mouse CYP1B1 has been puriˆed from C3H W 10T1 W 2 CL8 cells derived from an embryonicˆbroblast and the puriˆed enzyme catalyzes oxidation of 7, 12-DMBA. 15) Homologous rat CYP1B1 has also been isolated from adrenal microsomes and it catalyzed PAH metabolism. 16) Human CYP1B1 cDNA was isolated and the protein was expressed in yeast. 17, 18) Yeast microsomes containing human CYP1B1 was found to activate diverse procarcinogens including PAHs, aryl-and heterocyclic amines, and nitroarenes to genotoxic products in S. typhimurium NM2009 tester strain. 19) Interestingly, a close resemblance of substrate speciˆcities was found in CYP1A1 and 1B1 towards activation of various PAH-diols (Fig. 4) . 20) (±)-, (＋)-, and (-)B[a]P-7,8-diols, 7,12-DMBA-3,4-diol, DB[a,l] P-11,12-diol, 5-methylchrysene-1,2-diol, and B[a]A-3,4-diol, which are carcinogenic in experimental animals, 1, 21, 22) were highly activated by CYP1A1, and CYP1B1*1 (wild type of CYP1B1) and CYP1B1*3 (a R 48 A 119 V 432 N 453 CYP1B1 variant) at similar rates. CYP1A2 had slower rates in activating these PAHdiols. CYP1 enzymes also activate other carcinogenic PAH-diols, such as chrysene-1,2-diol, 5,6-methylchrysene-1,2-diol, benzo[g]chrysene-1,2-diol, and benzo[b]‰uoranthene-9,10-diol at relatively slower rates. 19, 20) As expected, B[a]P4,5-diol, 7,12-DMBA-5,6-diol, and B[a]A-1,2-, 5,6-and 8,9-diols, ‰uoranthene-2,3-diol, and benzo[j]‰uoranthene-4,5-diol, which do not form diol-epoxides, 1, 2) were not activated by P450s. CYP2C9 and 3A4 activate PAH-diols at much slower rates than CYP1 enzymes, but other human P450s (CYP2A6, 2C8, 2D6, 2E1, and 4A11) do not show any activities in this assay system. 20) Very recently, Wu et al. reported that human CYP2W1, which is found in tumor tissues from various organs, catalyzes activation of PAH-diols to genotoxic metabolites in S. typhimurium NM2009, although the rates were much slower than Tsutomu SHIMADA those by CYP1B1. 23) Question arises which P450s play key roles in activating PAHs in vivo. Buters et al. 24) reported that CYP1B1-null mice, being defective in activating 7,12-DMBA, are resistant to cytotoxicity and formation of malignant lymphomas and other tumors caused by 7,12-DMBA. DB[a,l]P has also been reported to be inactive in forming any type of malignant or benign tumor in ovaries or lymphoid tissues in CYP1B1-null mice.
25) The results of Luch et al. 26) suggest that CYP1B1 plays more important role than CYP1A1 in activating DB[a,l]P to highly reactive DB[a,l]P-11,12-diol-13,14-epoxides.
Recently, Uno et al. 27) reported that CYP1A1 may be involved in detoxiˆcation and protection against oral B[a]P in mice, since CYP1A1 null mice died within 30 days after oral B[a]P administration of 125 mg W kg, while wild-type mice did not show any signs of toxicity during the course of experiments. B[a]P-DNA adducts were higher in CYP1A1 null mice than the wild type mice. 27) Very recently, they also found using CYP1A1-, 1A2-, and 1B1-null mice and their double knockout mice that CYP1A1 is involved more directly in detoxiˆ-cation of oral B[a]P than activation and that CYP1B1 is responsible for activation of B[a]P to reactive metabolites that cause immune damage in spleen and bone marrow. 28) It is interesting in this connection to note our in vitro studies that human CYP1B1 has about 10-fold higher activity than CYP1A1 in converting B[a]P to a proximate carcinogen B[a]P-7,8-diol when rat and human EH are included in the reconstituted enzyme system. 29) Expression and Induction of CYP1A1, 1A2, and 1B1 by PAHs
Expression of human CYP1A1, 1A2, and 1B1 has been shown to be diŠerent in several organs examined. 30) CYP1A2 is predominantly expressed in the liver. In contrast, CYP1A1 and 1B1 are expressed mainly in extra-hepatic organs, although there are diŠerences between CYP1A1 and 1B1 in the levels of expression at diŠerent organs of humans. 19, 31) CYP1B1 mRNA is found in kidney, mammary gland, uterus, ovary, prostate, thymus, adrenal, spleen, heart, lung, brain, placenta, testis, small intestine, peripheral leucocytes, and pituitary, but not in pancreas. 19, 32) In most cases, the expression of CYP1A1 in these organs is shown to be lower than that of CYP1B1, except in pancreas, small intestine, and colon. 19, 32, 33) CYP1B1 mRNA has been detected in human fetal tissues, such as kidney, heart, lung, adrenal gland, and brain, and in human tumors such as breast cancer cells, uterine myoma, and renal adrenocarcinoma. 19, [31] [32] [33] [34] AhR plays key role in the regulation of CYP1A1, CYP1A2, and CYP1B1 and other enzymes by PAHs, TCDD, and 3,4,3?,4?-TCB that have been shown to be high-a‹nity AhR ligands. 35, 36) Mechanisms underlying induction of CYP1A1 by these chemicals have been studied extensively and reviewed elsewhere. [35] [36] [37] [38] [39] CYP1A2 and 1B1 are also regulated by AhR as those for CYP1A1, but diŠerences exist in the regulation of these P450s in mammals. 35, 40) For example, tissue-and sex-dependent expression have been reported to be diŠerent in CYP1A1, 1A2, and 1B1 and several lines of evidence support the view that these P450s are regulated independently through AhR-dependent and other mechanisms. 31, 33, 36) There are genetic polymorphisms in AhR gene in humans as well as in experimental animals. 41) Historically, mouse AhR gene has extensively been studied using arylhydrocarbon responsive C57BL W 6J mice and nonresponsive DBA W 2J mice. 42) By comparing AhR genes in two inbred strains of mice, two alterations that cause decreased a‹nities to AhR ligands have been found in AhR gene in DBA W 2J mice. 43, 44) One is an amino acid change at residue 375 of alanine in C57BL W 6J mice to valine in DBA W 2J mice and the other is that DBA W 2J mice have an elongated C-terminal sequence due to a mutation at the termination codon of the gene. Both changes cause reduced a‹nities to AhR ligands such as TCDD and PAHs. [43] [44] [45] Human AhR gene is structurally similar to that of DBA W 2J mice; the human protein has an amino acid of valine at residue 381 (instead of 375 in DBA W 2J mice) and an elongated C-terminal sequence by a T to C mutation at the terminal codon of AhR gene. 42, 43) Weak response of human AhR to TCDD and PAHs has been studied in vivo using AhRhumanized mice in which mouse gene has been replaced by human AhR gene. Toxic eŠects caused by TCDD found in C57BL W 6J mice were greatly reduced in AhRhumanized mice as well as in DBA W 2J mice, being functionally less responsive to TCDD in humanized mice than in DBA W 2J mice. 46) It is interesting to determine if there are diŠerences in levels of expression of CYP1A1 and 1B1 in diŠerent organs of animals at physiological states and how CYP1A1 and 1B1 are induced by typical AhR ligands in animals targeted for AhR gene. In a model study, we compared levels of expression of CYP1A1 and 1B1 in diŠerent organs of wild-type and AhR knockout mice (Fig. 5) . 47, 48) P450 mRNA levels in liver, heart, kidney, intestine, and testis were determined in male mice, and those in lung, thymus, uterus, ovary, and brain were determined in female mice. Constitutive expression (without chemical inducers) of CYP1A1 was very low in liver, heart, kidney, intestine, testis, lung, thymus, uterus, ovary, and brain in both wild-type and AhR (-W -) mice. In contrast, CYP1B1 was found to be expressed at signiˆcant levels in extra-hepatic organs such as heart, kidney, intestine, testis, thymus, uterus, ovary, and brain in both wild-type and AhR(-W -) mice. Constitutive expression of CYP1B1 in male livers and female lungs was low as in cases of CYP1A1.
Induction of CYP1A1 and 1B1 mRNAs was also determined in these organs of wild-type and AhR (-W -) mice using inducers of B[a]P and 3,4,3?,4?-TCB in males and 3-MC and 3,4,3?,4?-TCB in females (Fig. 5) .
48) The inducers were administered once i.p. at 100 mg W kg body weight and at 72 h later the mice were sacriˆced. CYP1A1 was highly induced in diŠerent organs by B 3,4,3?,4?-TCB induced CYP1A1 by about 30-and 60-fold in lung, 22-and 21-fold in thymus, 28-and 20-fold in uterus, 35-and 40-fold in ovary, and 28-and 21-fold in brain, respectively. However, the extents of induction of CYP1B1 in wild-type mice were lesser than those seen in CYP1A1 in extra-hepatic organs where the constitutive levels of CYP1B1 were apparently higher than those of CYP1A1. In males, B[a]P and 3,4,3?,4?-TCB induced CYP1B1 by only about 3.0-and 3.1-fold in heart, 1.8-and 1.6-fold in kidney, 3.3-and 2.2-fold in intestine, and 1.1-and 1.4-fold in testis, respectively. Similarly, 3-MC and 3,4,3?,4?-TCB induced CYP1B1 only weakly at thymus, ovary, and brain of female mice. It should also be mentioned that CYP1B1 in testis and ovary was not induced by PAHs and 3,4,3?,4?-TCB. On the other hand, in organs where the constitutive levels of CYP1B1 are relatively low, the extents of induction of CYP1B1 were signiˆcant. For example, B[a]P and 3,4,3?,4?-TCB induced liver CYP1B1 mRNA by 16-and 19-fold, respectively, in male mice, and 3-MC and 3,4,3?,4?-TCB induced lung and uterus CYP1B1 signiˆcantly, in female mice.
We also determined induction of CYP1A1, 1A2, and 1B1 mRNAs by 23 PAHs and compared with those by well-known CYP1 inducer 3,4,3?,4?-TCB in livers of male mice (Figs. 6 and 7) . [49] [50] [51] PAHs that are reported to be carcinogenic in experimental animals signiˆcantly induced liver CYP1A1, 1A2, and 1B1 mRNA levels and . Other PAHs such as 1-nitropyrene and B[e]P, and non-carcinogens ‰uoranthene, acenaphthylene, pyrene, anthracene, acenaphthene, and phenanthrene did not induce these P450s at signiˆcant levels.
As described in previous section, CYP1A1 and 1B1 play important roles in the activation of PAHs to reactive metabolites that cause initiation of tumor formation in diŠerent organs. However, marked diŠerences exist in constitutive expression of CYP1A1 and 1B1 in diŠerent organs of wild-type and AhR (-W -) mice as well as of humans. The high levels of constitutive expression of CYP1B1 in several extrahepatic organs may explain why CYP1B1-null mice are resistant to the toxicity and carcinogenesis caused by 
Inhibition of CYP1A1 and 1B1 by Various Chemicals
Since most of the carcinogenic PAHs are mainly metabolized by CYP1A1 and 1B1 to reactive metabolites, it is expected that chemical inhibitors of CYP1A1 and 1B1 may have chemopreventive activities. 52) aNaphtho‰avone, synthetic organoselenium compounds such as 1,2-, 1,3 and 1,4-phenylenebis(methylene)-selenocyanate (o-, m-and p-XSC, respectively), vinylic and acetylenic polycyclic aromatic hydrocarbons such as 1-(1-propynyl)pyrene, 2-(1-propynyl)phenanthrene, 1-ethynylpyrene, 2-ethynylpyrene and 4-(1-propynyl)-biphenyl have been shown to inhibit CYP1A1 and 1B1. [53] [54] [55] Recently, Chun et al. 55, 56) reported that the natural products, resveratrol and rhapontigenin, are potent inhibitors of human CYP1A1, while 2,4,3?,5?-tetramethoxystilbene inhibits CYP1B1 selectively.
Some of these chemical inhibitors of CYP1A1 and 1B1 have been reported to suppress tumor formation caused by carcinogenic PAHs in experimental animals. [56] [57] [58] [59] [60] [61] [62] [63] [64] p-XSC prevents mammary tumor formation by 7,12-DMBA and o-and m-XSC inhibit 7,12-DMBA-DNA adduct formation in rats. 60, 65) These synthetic organoselenium compounds inhibit human CYP1B1 more strongly than CYP1A1. 53) Likewise, 1-ethynylpyrene inhibits covalent binding of 7,12-DMBA and B[a]P to epidermal DNA 66) and prevents tumor formation caused by 7, 12-DMBA and B[a]P in mouse skin 67) ; 1-ethynylpyrene has been shown to inhibit both CYP1A1 and 1B1. 54) Resveratrol, which inhibits CYP1 enzyme activities, prevents tumor formation caused by 7,12-DMBA in mice. 55, 62, 68) Very recently, carcinogenic PAHs, such as B[a]P and 5-methylchrysene are shown to inhibit CYP1A1-and 1B1-dependent 7-ethoxyresoruˆn O-deethylation activities (Fig. 8) .
69) IC50 values of the inhibition of CYP1A1-dependent 7-ethoxyresoruˆn O-deethylation activities by B[a]P and 5-methylchrysene were 350 nM and 135 nM, respectively, whereas those of CYP1B1-dependent activities by these PAHs were 31 nM and 8.0 nM, respectively (Figs. 8A and 8D) . B[a]P and 5-methylchrysene also inhibit metabolic activation of B[a]P-7,8-diol and 5-methylchrysene-1,2-diol to genotoxic metabolites by CYP1A1 and 1B1 in S. typhimurium NM2009 (Figs. 8B, 8C, 8E, and 8F) . The results are of interest, since PAHs can inhibit metabolism of their own and other carcinogenic PAHs catalyzed by CYP1A1 and 1B1. These events may explain why a complex mixture from broiled food or coal tar is sometimes less active in producing tumors, as compared with those administered with a single carcinogen at a same dosage present in the mixture. 3, 70) Genetic Polymorphism of Enzymes Involved in Metabolism of PAHs Overview: In recent years, genetic polymorphism of a variety of xenobiotic-metabolizing enzymes has been studied extensively. [71] [72] [73] [74] In general, genetic polymorphisms of enzymes do not always lead to changes in protein expression and catalytic activities (see http:www.imm.ki.se W CYPalleles). However, in many cases, the gene mutations cause alterations in expression and function of enzymes, and are considered to be key factors in contributing to diŠerent susceptibilities of individuals towards action of xenobiotic chemicals. 73, 74) Numerous epidemiological studies have been done to ascertain whether genetic polymorphisms of xenobioticmetabolizing enzymes are related to cancer susceptibilities in humans. [71] [72] [73] [74] Some of the results show positive correlations between polymorphisms of selected enzymes and the occurrence of particular cancers in humans. However, other studies do not support the results, even when the same combination of enzymes and sites of cancers are compared. There are race-related diŠerences in genetic polymorphism of xenobioticmetabolizing enzymes in humans, and these phenomena may explain, in part, why such diŠerent results are obtained between laboratories. 71, [75] [76] [77] Other factors such as age, sex, pathological and physiological conditions, and exposure to environmental pollutants in‰uence to the epidemiological data obtained in diŠerent laboratories. 78) It should also be mentioned that individuals have diŠerent and unique combinations of polymorphic forms of xenobiotic-metabolizing enzymes. For example, some of the people have defective enzymes that activate PAHs, but they have normal enzymes that detoxify PAHs. In contrast, other people have normal enzymes that activate PAHs but have defective enzymes that detoxify reactive PAH metabolites. In these cases, epidemiological studies are di‹cult to interpret which polymorphisms of xenobiotic-metabolizing enzymes are mainly involved in cancer susceptibilities. In addition, it remains unclear if there are other genetic polymorphisms that have not been identiˆed yet and these mutations in‰uence strongly to cancer susceptibilities by PAHs.
In the following section, we brie‰y discuss the catalytic properties and genetic polymorphisms of P450s (CYP1A1, 1A2, 1B1, 2C9, and 3A4) and phase II enzymes (EH, GST, UGT, SULT, NQO1, and AKR) that are principally involved in activation and detoxiˆ-cation of PAHs.
CYP1A1: CYP1A1 wasˆrst isolated from liver microsomes of mice, rats, and rabbits that had been treated with 3-MC and b-naphtho‰avone.
2,14,79)
CYP1A1 had been thought to be a principal enzyme responsible for the metabolic activation of B[a]P and other carcinogenic PAHs, until CYP1B1 was found in mice, rats, and humans. [15] [16] [17] [18] [19] Human CYP1A1 was puriˆed from lung microsomes, but aˆnal preparation was devoid of heme, probably due to its unstable nature during puriˆcation. 80) Human CYP1A1 has been expressed in diŠerent recombinant systems and its catalytic properties have been determined. 81, 82) CYP1A1 has relatively similar, but diŠerent, substrate speciˆci-ties to CYP1B1 in the metabolism of PAHs and other carcinogens. 19, 20) CYP1A1 also catalyzes oxidation of several xenobiotic chemicals including 7-ethoxyresorun, theophylline, caŠeine, 7-ethoxycoumarin, and chlorzoxazone and endogenous chemicals including 17b-estradiol and estrone. [81] [82] [83] [84] At least 11 alleles of CYP1A1 have been identiˆed (see http: W W www.imm.ki.se W CYPalleles). CYP1A1 * 2B, *2C, *3, *4, *5, *6, *7, *8, *9, *10, and *11 show amino acid changes. It remains unclear whether these amino acid changes cause alterations in catalytic activities towards oxidation of xenobiotics, including PAHs. For example, a variant (I462V) of CYP1A1 does not show any major diŠerences with the wild type enzyme (CYP1A1*1) in catalytic activities towards various substrates. 85, 86) Two mutually linked polymorphisms of the human CYP1A1 gene, the MspI polymorphism (*2A) located in the 3?-‰anking region and the Ile-Val polymorphism (*2B) at residue 462 in the heme binding region, have been reported to associate with susceptibility to smoking-associated squamous cell carcinoma of the lung in Japanese population. [87] [88] [89] However, this association has not been found in other ethnic groups. [90] [91] [92] CYP1A1*3 polymorphism, which is present more frequently in African-Americans, has been reported to be a risk factor in the occurrence of adenocarcinoma 93, 94) , although other studies do not support the results. 77, 95) CYP1A1*5 polymorphism (Thr461Asn) has been reported to be a risk factor in lung cancer susceptibilities. 96) Race-related diŠerences in genetic polymorphism of CYP1A1 have been reported. 76, 77) MspI (CYP1A1*2A polymorphism) and Ile-Val (CYP1A1*2C polymorphism) polymorphisms were found to be more frequent in Japanese than Caucasians. The CYP1A1 * 3-type polymorphism, a speciˆc type for African black, has not been found in both Japanese and Caucasian populations and CYP1A1*4 polymorphism has not been reported in Japanese. DiŠerent distributions of genetic polymorphisms of CYP1A1 have also been reported in other ethnic groups. 73, 74, 77, [93] [94] [95] [96] [97] [98] CYP1A2: CYP1A2 is mainly expressed in the liver.
99) The human enzyme wasˆrst isolated from liver microsomes by monitoring phenacetin O-deethylation activity and the puriˆed enzyme was termed P450PA. 100) Tobacco-smoke condensates and broiled foods have been shown to induce human CYP1A2. 101, 102) The levels of CYP1A2 protein are found to be ¿10¿15z of total P450 in human adult livers and the expression levels vary about 40-fold among individuals. 99) CYP1A2 catalyzes metabolic activation of a variety of aryl-and heterocyclic amines, such as 2-aminoanthracene, 2-acetylamino‰uorene, 2-amino-3,5-dimethylimidazo[4,5-f]quinoline (MeIQ), and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). [103] [104] [105] CYP1A2 also catalyzes the activation of PAH-diols to reactive metabolites at much slower rates than CYP1A1 and 1B1. 20) CYP1A2 oxidizes other xenobiotic chemicals including acetaminophen, antipyrine, caŠeine, 7-ethoxyresoruˆn, lidocaine, phenacetin, theophylline, and R-warfarin. 84, [99] [100] [101] [102] At least 24 genetic polymorphisms of CYP1A2 have been identiˆed (see http: W W www.imm.ki.se W CYPalleles). Alleles CYP1A2*2, *3, *4, *5, *6, *8, *9, * 10, * 11, * 12, * 13, * 14, * 15, and * 16 show amino acid changes. 74, [106] [107] [108] [109] In vitro studies revealed that a F186L (CYP1A2 * 11) mutation causes decrease in 7-ethoxyresoruˆn O-deethylation activities.
110) The CYP1A2*7 allele contains a splicing defect at the site of intron 6 (G3534A) and this change has been shown to cause decreases in clozapine concentrations in vivo.
106)
CYP1A2*1C genetic polymorphism is reported to lower in vivo caŠeine clearance in Japanese smokers.
107)
CYP1A2*1K (-T739G, -C729T, and -C163A) polymorphism has been shown to reduce CYP1A2 activity in vivo. 108) It is not fully understood whether CYP1A2 genetic polymorphism relates to cancer susceptibilities in humans.
CYP1B1: Native human CYP1B1 protein has not yet been isolated from human samples; the enzyme is predominantly expressed in the endoplasmic reticulum of extrahepatic organs. 19) A human CYP1B1 cDNA clone was isolated and characterized. 17, 18) The isolated clone that maps to chromosome 2 at 2p21-22 contained 5.1 kb sequence and a single open reading frame of 1629 bp that predicts a protein of 543 amino acids. 18, 111) The similarity of amino acid sequence of human CYP1B1 to those of rat and mouse CYP1B1 enzymes is determined to be 80z and 81z, respectively, and to be ¿40z with CYP1A1 and CYP1A2. 16, 18, 111, 112) As described above, human CYP1B1 mRNA is found in various extrahepatic organs in adults and fetus and in several tumors including breast cancer cells, uterine myoma, and renal adrenocarcinoma cells. 19, [30] [31] [32] [33] [34] [113] [114] [115] [116] [117] Human CYP1B1 plays important role in the activation of diverse procarcinogens including PAHs, aryl-and heterocyclic amines, and nitroarenes. 19, 20, 118) CYP1B1 also catalyzes O-deethylation of 7-ethoxyresoruˆn, 8-hydroxylation and 1-and 3-demethylations of theophylline, 3-demethylation and 8-hydroxylation of caŠeine, O-deethylation of 7-ethoxycoumarin, and 1?-hydroxylation of bufuralol. 82, 84) CYP1B1 converts estrogens to 4-hydroxylated metabolites that may cause initiation of breast cancer in humans. 34, 117) At least 23 variant forms of CYP1B1 have been identiˆed in humans; 17 of these variants show amino acid changes (http:www.imm.ki.se W CYPalleles). Null alleles of CYP1B1 are reported to relate to heredity glaucoma. 119, 120) Major CYP1B1 variants with amino acid changes at 48 (R48G), 119 (A119S), 432 (L432V), and 453 (N453S) have been studied in vitro in order to determine whether these amino acid changes cause alterations in catalytic activities towards 4-hydroxylation of 17b-estradiol and metabolic activation of PAHs to reactive metabolites. 20, [121] [122] [123] Collectively, these results suggest that such amino acid changes do not lead to major changes in catalytic activities.
Watanabe et al. 124) studied frequency distribution of CYP1B1 * 2 (Ala-Ser) and CYP1B1 * 3 (Leu-Val) polymorphisms in 336 breast and 330 lung cancer patients and 324 randomly selected healthy controls in Japanese population. They showed that CYP1B1*2 polymorphism is associated with genetically determined susceptibility to breast or squamous cell carcinoma of the lung, but the Leu-Val polymorphism does not. However, Zheng et al. 125) showed that genetic polymorphism of CYP1B1 at codon 432 (Val to Leu) is related to breast cancer risk in Chinese population. Rylander-Rudqvist et al. 126) reported that there are no association between CYP1B1*1, *2, *3, and *4 alleles and breast cancer risk in a study with 1521 cases and 1498 controls in Swedish women. No associations of polymorphisms of CYP1B1 or other genes (including GST, NQO1, and Nacetyltransferase 2) and lung cancer risk have been found in Danish population. 127) Race-related diŠerences exist in the occurrence of genetic polymorphism of CYP1B1 gene in diŠerent ethnic groups and care should be taken in analyzing epidemiological data obtained in diŠerent laboratories. 72, 73, 76) CYP2C9: CYP2C9 is mainly expressed in the liver with mean levels of ¿20z of total P450 in diŠerent human samples.
99) The enzyme catalyzes metabolism of a varity of clinically used drugs such as ‰ubiprofen, losartan, phenytoin, tolbutamide, and warfarin. 84, 99, 128) CYP2C9 also mediates 3-hydroxylation of B[a]P and metabolic activation of several PAH-diols to active metabolites at much slower rates than those by CYP1 enzymes. 20, 129) Genetic polymorphisms of CYP2C9 have been reported; more than 24 alleles are found (see http: W W www.imm.ki.se W CYPalleles). Alleles CYP2C9*2, *3, *4, and *5 have amino acid replacements, and these mutations are shown to reduce in vitro catalytic activities.
128,130-134) CYP2C9 * 3 has been shown to cause decreases in catalytic activities in vivo. 128, 131, 132) It remains unclear whether these genetic polymorphisms are related to cancer susceptibilities by PAHs in humans. 135) CYP3A4: CYP3A4 is the most abundant P450 in human livers and also in intestine; the mean levels of CYP3A4 in human livers are reported to be ¿30z of total P450. 99) The enzyme is induced by various barbiturates and macrolide antibiotics such as rifampicin. 136) CYP3A4 has been reported to metabolize about 50z of clinically used drugs, such as cyclosporine, dapsone, dextromethorphan, diazepam, ebastine, erythromycin, felodipine, FK506, gestodene, imipramine, lidocaine, lovastatin, midazolam, nifedipine, omeprazole, quinidine, roxithromycin, sulfamethoxazole, tamoxifen, terfenadine, troleandomycin, warfarin, and zonisamide. 84, 99, 136) CYP3A4 is also known to metabolize endogenous compounds such as testosterone, 5b-cholestane-3a,7a,12a-triol, and estrogens. 84, 136) In human livers, CYP3A4 activates mycotoxins such as a‰atoxin B1 and G1 and sterigmatocystin and PAH-diols to active metabolites. 104) Catalytic activities of CYP3A4 in activating PAHs are lower than those by CYP1 family enzymes. 20) More than 18 genetic polymorphisms of CYP3A4 have been reported (see http: W W www.imm.ki.se W CYPalleles). It is not fully understood whether these mutations cause changes in catalytic activities.
137) The signiˆcance of these polymorphisms in cancer susceptibilities remains unclear.
EH (epoxide hydrolase): Microsomal EH (mEH) catalyzes hydrolysis of various oxides of numerous endobiotic and xenobiotic chemicals into less reactive and more polar dihydrodiols. 138) Although mEHs have been shown to play important roles in detoxiˆcation of numerous oxide intermediates, they also mediate activation of PAHs to highly reactive diol-epoxides, in collaboration with P450s. 1) In fact, engineered mice lacking mEH gene have been shown to lower the metabolism of 7,12-DMBA to its 3,4-diol derivative and to be resistant to toxicity and carcinogenicity by 7,12-DMBA. 139) Two genetic polymorphisms, a Tyr113His substitution in exon 3 (EH3) and a His139Arg substitution in exon 4 (EH4), are reported with respect to cancer susceptibilities. 138, [140] [141] [142] The exon 3 polymorphism of mEH is reported to be a factor against lung cancer risk. 140, 143) However, other studies have shown that there are no signiˆcant association of mEH polymorphisms in lung cancer susceptibilities in Caucasian and Chinese populations. 144) It is reported that exon 3 and 4 polymorphisms of mEH at exon 3 and 4 are associated with colorectal adenoma. 145) GST (glutathione transferase): GSTs are constitutively expressed in various human tissues. 146) Cytosolic GSTs encoded by polymorphic members of alpha (GSTA), mu (GSTM1), pi (GSTP1), and theta (GSTM1) gene families play important roles in the metabolism of a variety of toxic and carcinogenic compounds, including PAH oxides and diol-epoxides. 147, 148) The levels of individual enzymes may be in‰uenced by induction and by genetic polymorphism. 3, 147, 148) Most of the glutathione conjugates are less toxic and more polar and can be excreted from the body. However, GSTs convert dichloromethane and short-chain alkyl halides to unstable and mutagenic glutathione conjugates. 146) Genetic polymorphisms of GSTM1, T1, and P1 have been reported in relation to cancer susceptibilities in humans. 146, 149) A larger study with 1,969 control and 2,048 lung cancer cases showed that none of the single GST polymorphism (e.g. GSTM1, T1, and P1) relate to a substantial risk of breast cancer. 150) Ntais et al.
151)
reported that there is no association of GSTM1 (2,063 cases versus 2,625 controls), T1 (1,965 cases versus 2,554 controls), and P1 (2,528 cases versus 3,076 controls) genotypes in prostate cancer risk. However, it is not precisely determined how GST polymorphisms relate to cancer susceptibilities in humans. 152, 153) UGT (UDP-glucuronosyltransferase): Glucuronidation is a major pathway for detoxiˆcation of numerous carcinogens such as PAHs and aryl-and heterocyclic amines. 3, 78) The UGT superfamily consists of two families, UGT1 and UGT2, and the latter family contains two subfamily members, UGT2A and UGT2B.
154) UGT1 has a unique gene structure in which there are thirteen exon 1s, from UGT1A1 to UGT1A13P, using exon 2 to 5 being in common in all mRNAs. 155) Nine functional UGT1 proteins have been found, namely UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10. UGT2 subfamily consists of 8 functional proteins (UGT2A1 and UGT2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28). 155, 156) Genetic polymorphisms have been found in UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9 and UGT2A1, 2B4, 2B7, 2B15, and 2B28. [155] [156] [157] Little is known about association of genetic polymorphisms of UGTs in cancer susceptibilities in humans.
SULT (sulfotransferase): Cytosolic SULTs catalyze sulfonation of a variety of carcinogens including PAHs. 158) Sulfonation is generally thought to be a detoxiˆcation process; however, in a few instances, the enzymes activate certain promutagens (such as 7,12-DMBA) to highly reactive sulfate esters that bind covalently to DNA. 159, 160) In humans, SULT consists of three families, namely SULT1, 2, and 4, and contains at least 13 members of proteins. 78, 161) SULT1A1, 1A2, 1A3, 1B1, 1C2, and 1C4 and SULT 2A1 are the major enzymes to catalyze hydrolysis of xenobiotic chemicals including carcinogens. 158) Genetic polymorphisms have been found in SULT1A1, 1A2, 1B1, 1C1, 1C2, and 2A1. 158, 161, 162) Among these cases, SULT1A1 * 2, which shows an amino acid change at position 213 from arginine to histidine, is reported to have lowered catalytic activity. [161] [162] [163] Epidemiological studies revealed that SULT1A1 polymorphisms relate to risk factor for breast, lung, and bladder cancer, although other studies do not conˆrm the results. [161] [162] [163] [164] [165] NQO1 (NAD(P)H quinone oxidoreductase 1): NQO1 is induced by PAHs and TCDD through AhR. 166) The enzyme, formerly referred to as DT-diaphorase, catalyzes two-electron reduction of a wide variety of substrates, including PAH o-quinone, to inactive products, such as PAH-hydroquinones. 166) NQO1 has been shown to convert benzene-derived quinones to more inactive hydroquinones, thus protecting benzeneinduced hematotoxicity.
166) It has also been reported that skin tumors caused by B[a]P and 7,12-DMBA are increased in NQO1 knock-out mice, indicating that NQO1 might be involved in detoxiˆcation of PAHs (probably PAH o-quiones) to inactive PAH hydroquinones. 11, 167) In a few instances, NQO1 activates some of the antitumor agents, such as mitomycin C and streptonigrin, to reactive metabolites that are toxic in tumor cells as well as normal cells. 168) A genetic polymorphism of NQO1, a C to T transition at nucleotide 609, which yields a proline to serine substitution at residue 187, has been shown to cause reduced NQO1 activity. 169) Saldivar et al. 169) and Lewis et al. 170) showed that individuals with reduced activities due to NQO1 polymorphism are associated with an increased risk of lung cancer susceptibilities. Sunaga et al. 171) reported that NQO1 and GSTT1 polymorphisms are related to lung cancer susceptibilities. However, none of the association between NQO1 polymorphism and lung cancer susceptibilities have been found in Caucasians and Hawaiians. 172) Racerelated diŠerences in NQO1 polymorphisms have been reported. 166) More detailed examinations are required to determine if NQO1 deˆciencies relate to cancer susceptibilities in humans. [169] [170] [171] [172] [173] AKR (aldo-keto reductase): AKRs, the soluble NAD(P)H-dependent oxidoreductases, have recently been shown to convert PAH trans-dihydrodiols to reactive PAH o-quinones that form stable and depurinating DNA adducts. 8, 9) Thus PAH-diols are shown to be activated by two enzymatic activities, namely to PAH diol-epoxides by P450s and to PAH o-quinones by AKRs. Human AKR1A1 (aldehyde reductase) and AKR1C1, 1C2, 1C3, and 1C4 (hydroxysteroid W dihydrodiol dehydrogenases) are the major enzymes involved in catalyzing PAH diols to o-quinones and recent studies have established that AKR1A1 is more active than other AKR enzymes in metabolizing B[a]P-7,8-diol, 5-methylchrysene-7,8-diol, B[a]A-3,4-diol, 7-methylbenz[a]anthracene-3,4-diol, and 7,12-DMBA-3,4-diol. 8, 9, 174, 175) Detailed examination of genetic polymorphisms of AKR genes involved in the metabolism of PAHs is lacking at present.
Conclusion
Xenobiotic-metabolizing enzymes play key roles not only in the detoxiˆcation of PAHs but also in the activation of PAHs to active metabolites. CYP1A1 and 1B1 enzymes in collaboration with EH have major roles in activating PAHs to highly reactive diol-epoxides that are proposed to be ultimate carcinogenic metabolites. Recent studies have established that CYP1B1 may have more important roles than CYP1A1 in activating PAHs to toxic and carcinogenic metabolites based on the results reported so far. First, tumor formations caused by B[a]P and DB[a,l]P have been shown to be dramatically suppressed in CYP1B1-null mice, probably due to decreased formation of reactive PAH metabolites that might be catalyzed by CYP1B1. 24, 25) Second, human CYP1B1 has been shown to convert B[a]P to B[a]P-7,8-diol at 10-fold higher rates than CYP1A1 when rat and human EH are included in the incubation mixture. 29) Third, in both wild-type and AhR(-W -) mice, CYP1B1 has been shown to be constitutively expressed more abundantly than CYP1A1 in most of the extrahepatic organs where several types of tumors are experimentally produced with carcinogenic PAHs. 47, 48) Finally, CYP1A1 is reported to play more important roles in detoxiˆcation than activation of oral B[a]P when it is compared of its toxic eŠects in mice that had been disrupted in CYP1A1, 1A2, or 1B1 gene. 27, 28) Recent studies have revealed that PAHs are also activated by other enzymatic activities as well as P450 activities; e.g. PAHs are catalyzed by peroxidase activities to radical cations that form depurinatind DNA adducts, and PAH-diols are converted by AKRs to PAH o-quinones that form stable and depurinating DNA adducts. [6] [7] [8] [9] [10] 13) The reactive metabolites, thus formed, are usually detoxiˆed to more polar products by phase II enzymes, such as UGT, GST, SULT, and NQO1. Inter-individual diŠerences exist in the levels of expression and catalytic activities of a variety of xenobiotic-metabolizing enzymes in humans and these phenomena are thought to be critical in understanding the basis of diŠerent susceptibilities of individuals to the action of PAHs.
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